BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. AWK
9. ACN
10. USO

Go back to BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
(NASDAQ: BTAI) Delayed: 1.26 -0.04 (3.08%)
Previous Close $1.30    52 Week High $ 
Open $1.28    52 Week Low $ 
Day High $1.33    P/E N/A 
Day Low $1.25    EPS $ 
Volume 724,073